MyMyelomaTeam

Teclistamab (brand name Tecvayli) is a newer FDA-approved treatment option for multiple myeloma. It works differently from Darzalex by using bispecific antibodies that help your T-cells recognize and attack myeloma cells.

Clinical trials have shown promising results, with about 62% of participants responding to the Show Full Answer

Teclistamab (brand name Tecvayli) is a newer FDA-approved treatment option for multiple myeloma. It works differently from Darzalex by using bispecific antibodies that help your T-cells recognize and attack myeloma cells.

Clinical trials have shown promising results, with about 62% of participants responding to the treatment. Even better, after 9 months of treatment, about 67% of people were still responding well. While Teclistamab can be effective, it's important to know that it's typically used in cases where other treatments haven't worked (relapsed or refractory myeloma). The treatment binds to specific proteins on myeloma cells and activates your immune system's T-cells to target them. Your healthcare team can help determine if this might be a good next step based on your specific situation and treatment history.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

What Is BCMA-Targeted Immunotherapy?

Bispecific T-Cell Engagers for RRMM: 6 Facts About a New Type of Treatment